Thursday, May 16, 2019

Why lymphoma patients may become resistant to specific therapy

Researchers have discovered a mechanism of drug resistance to Venetoclax®, also known as ABT-199, a BCL-2 targeting drug commonly used to treat chronic lymphocytic leukemia and acute myeloid leukemia. Their findings also suggest a possible co-treatment strategy to overcome this resistance.

from Top Health News -- ScienceDaily http://bit.ly/30illJv
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Scientists discover a protein switch that burns fat and blocks new fat cells

A protein called “Mitch” may hold the key to a new generation of obesity treatments. Researchers found that disabling it in human cells boos...